

pVAC1-mcs

A plasmid designed for the production of neutralizing antibodies

Catalog code: pvac1-mcs

For research use only

Version 20K25-MM-35

PRODUCT INFORMATION

Contents:

- 20 µg of lyophilized pVAC1-mcs plasmid DNA.
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

- Products are shipped at room temperature.
- Lyophilized DNA is stable 12 months when stored at -20°C.
- Resuspended DNA is stable 12 months when stored at -20°C. Avoid repeated freeze-thaw cycles.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

- Plasmid DNA was prepared using affinity column and lyophilized.
- Plasmid construct has been confirmed by restriction analysis sequencing.

GENERAL PRODUCT USE

pVAC1-mcs is a DNA vaccine vector specifically designed to stimulate a humoral immune response by intramuscular injection. Antigenic proteins are targeted and anchored to the cell surface by cloning the gene of interest in frame between the IL2 signal sequence and the C-terminal transmembrane anchoring domain of the placental alkaline phosphatase (PLAP). The antigenic peptide produced on the surface of muscle cells is thought to be taken up by antigen presenting cells (APCs) and processed through the major histocompatibility complex (MHC) class II pathway^{1, 2, 3}.

pVAC1-mcs may be used to:

Clone a gene encoding an antigenic protein of your choice. pVAC1-mcs is designed for the cloning of an antigenic gene that is not naturally secreted. A multiple cloning site (MCS) is located downstream of the promoter for convenient cloning of an antigenic gene. The MCS contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.

Express an antigenic protein directly within transfected cells. The expression of the antigenic protein is driven by the strong rhesus monkey EF1 promoter. The expressed protein is secreted and anchored to cell membrane since the MCS is inserted between the IL2 signal sequence and the glycosylphosphatidylinositol (GPI) anchoring domain of human PLAP.

Note: Make sure the open reading frame of the antigenic gene is cloned in phase with the IL2 signal sequence.

PLASMID FEATURES

- **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells. Furthermore, the SV40 enhancer is able to direct nuclear localization of plasmids.
- **rhEF1 prom:** The elongation factor-1 alpha (EF-1α) is one of the most abundant proteins in eukaryotic cells and is expressed in almost all kinds of mammalian cells. The promoter of this 'housekeeping' gene exhibits a strong activity, higher than viral promoters such as SV40 and RSV promoters and, on the contrary to the CMV promoter, yields persistent expression of the transgene *in vivo*. The rhesus monkey EF-1α promoter shares 92.9% homology with its human counterpart and displays an activity similar to the human EF-1α promoter.
- **IL2 ss:** The IL2 signal sequence contains 21 amino acids and share common characteristics with signal peptides of other secretory proteins with respect to abundance and positions of hydrophobic amino acids. The intracellular cleavage of the IL2 signal peptide occurs after Ser20 and leads to the secretion of the antigenic protein
- **MCS** contains the following restriction sites:
Bam HI, *Eco* RV, *Bgl* II, and *Eco* RI
 - *Bam* HII is compatible with *Bgl* I, *Bst* YI and *Bcl* I.
 - *Eco* RV is compatible with any other blunt-end restriction enzymes.
 - *Bam* HII is compatible with *Bgl* I, *Bst* YI and *Bcl* I.
 - *Eco*RI is compatible with *Apo* I, *Mfe* I and *Tsp* 509I.

- **PLAP sa** is a hydrophobic COOH-terminal sequence of 32 residues which is eliminated during processing of the preprotein. The proteolytic cleavage of the C-terminal propeptide after Asp3 is catalyzed by a transaminase which simultaneously adds a GPI tail to the Asp residue.
- **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.
- **pMB1 ori:** a minimal *E. coli* origin of replication to limit vector size but with the same activity as the longer Ori.
- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Sh ble-ΔCpG** is a new allele of the *Sh ble* gene conferring resistance to Zeocin™. In order to reduce the immunogenicity of this bacterial gene all CpG motifs have been removed by chemically synthesizing the gene. The *Sh ble-ΔCpG* gene allows the selection of *E. coli* clones transformed with the pVAC plasmid.
Note: Stable transfection of clones cannot be performed due to the absence of an eukaryotic promoter upstream of the *Sh ble-ΔCpG* gene.
- **Term:** The *E. coli rpmB/G* terminator allows efficient transcription termination of the *Sh ble-ΔCpG* gene.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

References:

1. Corr M. *et al.*, 1999. In vivo priming by DNA injection occurs predominantly by antigen transfer. *J Immunol.* 163(9):4721-7.
2. Forns X. *et al.*, 1999. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. *Vaccine* 17:1992-2002.
3. McCluskie M.J. *et al.*, 1999. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. *Mol Med* 5:287-300.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873


InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-34-80

E-mail: info@invivogen.com





100

PstI (6)
SdaI (6)

Acc65I (43)

PvuII (69)

1 CCTGCAGGGCCTGAAATAACCTCTGAAAGAGGAACCTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTGTGGAATGTGTGCAGTTAGGGTGTGGAA
 101 AGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCAGGCTCCCCAGCAGGCAGAAG

SpeI (243)

201 TATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCACTAGTGGAGCCGAGAGTAATTCATACAAAAGGACTCGCCCTGCCTTGGGGAATCCC
 301 AGGGACCGTCTGTTAAACTCCCACTAACCTAGAACCAGAGATCGTTCGTTCCCGCCCTCACACGCCGCTCTCGTCATACCAAGGTGGAGAAGAC

AgeI (487)

401 ATGCGTGAGGCTCCGGTGCCCGTCACTGGGAGAGCGCACATCGCCACAGTCCCGAGAAAGTTGGGGGAGGGGTGGCAATTGAACCGGTGCCTAGAG
 501 AAGGTGGCGGGGTAAACTGGGAAAGTATGTCGTGTACTGGCTCCGCCTTTTCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGCTGTG

Psp1406I (602)

601 AACGTTCTTTTTTCGCAACGGTTTCCGCCAGAACACAGgtaagtactgtgtggtcctgcgggcctggcctctttacgggctatggccctcgctgc

NcoI (719)

StuI (784)

701 cttttattacttacacgcccattggcgcgtgtacgtgattcttgatcccagcctcgggttggaaagtgggtgggagaggtcgaggccttgacttaaggag

StuI (827)

801 tcccttcgctcgtgcttgagtcgagggcctggccttgggctctggggctgcccgcgtgcgaatctggtagcaccttcgcccctgcccgcctgctttactaa

PvuII (932)

901 gtttctagccatttaaaatTTTTgatgaccagctgcaacgcctTTTTctggcgagataatcttataaatgaggaccaggatctgcacactgatattggg

SacII (1014)

BspLU11I (1046)

1001 gttttgggggcccgcgggctgcgacgggctcgtgctcccagcgcacatgttcggcgagggcgggctgcgagcggccaccgagagtcggacgggggg

SacII (1145)

1101 agtctcaagctggccgctcctgctctggtgccggcctcgcgccgggtgtgctccccgcctggcggcaagcctggcccggctggcaccagttgcgtg

XmaI (1261)

1201 agcggaaagatggccgcttcccggccctgccgcagggagctcaaaatggaggacgcggcgcccgggagagcgggctgagtcacccacacaaggaaa

BbsI (1390)

1301 agggcctttccctcctcggctgcgcgcttcatgtgaccccagagtagccgggcccgtccaggcacctcgattagttctccgagcttttgagtagctct

Bsu36I (1403)

1401 tccttaggtttgggggaggggtttgtgctggtggagtttccccacacttgggtgggagactgaagagttaggccagcttggcgtcgtgatgtaattctc

BstBI (1518)

HindIII (1544)

1501 cttggaatttgcccttttcgaatttggatcttgcttattctcaagcttcagacagtggttcaaagtTTTTTTTctccatttcagGTGTCGTGAAAAC

BamHI (1681)

EcoRV (1697)

1601 ACCCTAAAAGCCATcATGTATAGGATGCAACTGCTGTCTTGCACTTGTCTGTCTGGCACTGGTCACTAACTCTGCCAGGATCCAGAGCTCAGATATC
 1 M Y R M Q L L S C I A L S L A L V T N S A

EcoRI (1709)

BglII (1702)

1701 CAGATCTTGAATTCACCACTGATGCTGCCATCCTGGAAGGTCTGTGGTGCCTGCCTTGTGCCTTGTCTGGCTGGCACTCTGCTGCTGCTGGAGACTGC
 1 T T D A A H P G R S V V P A L L P L L A G T L L L L E T A

NheI (1820)

MscI (1900)

1801 CACTGCTCCCTAAACCTGAGCTAGCATTATCCCTAATACCTGCCACCCACTTAAATCAGTGGTGAAGAACGGTCTCAGAAGTGTGTTTCAATTGG
 29 T A P •

1901 CCATTTAAGTTTAGTAGTAAAAGACTGGTTAATGATAACAATGCATCGTAAAACCTTCAGAAGGAAAGGAGAATGTTTTGTGGACCACCTTGGTTTTCTT

2001 TTTTGCCTGTGGCAGTTTTAAGTTATTAGTTTTTAAAAATCAGTACTTTTTAATGGAAACAACCTTGACCAAAAATTTGTACAGAATTTTGAGACCCATTA

2101 AAAAAAGTTAAATGAGAAACCTGTGTGTTCTTTGGTCAACACCAGACATTTAGGTGAAAGACATCTAATTCTGGTTTTACGAATCTGGAAACTTCTTGA

HpaI (2218)

2201 AAATGTAATTCCTGAGTTAACACTTCTGGGTGGAGAATAGGGTGTGTTTCCCCCACATAATTGGAAGGGGAAGGAATATCATTTAAAGCTATGGGAGGG

HindIII (2394)

2301 TTGCTTTGATTACAACACTGGAGAGAAATGCAGCATGTTGCTGATTGCCTGTCACTAAAACAGGCCAAAAACTGAGTCCCTGTGTTGCATAGAAAGCTTC

PacI (2485)

2401 ATGTTGCTAAACCAATGTTAAGTGAATCTTTGAAACAAAATGTTTCCAAATTAAGTGGATGTGCATGTTGAAACGTGGGTTAATTAACCTAGCCATGACC
 2501 AAAATCCCTTAACGTGAGTTTTCTGTTCCACTGAGCGTCAGACCCGTAGAAAAGATCAAAGGATCTTCTTGTGATCCTTTTTTCTGCCGCTAATCTGCT
 2601 GCTTGCAACAAAAAACACCCTACAGCGGTGTTGTTTGGCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACCTGGCTTACAGCAGAGCGCA

2701 GATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCA
2801 GTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGGCTGAACGGGGGGTTCGT
2901 GCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGCGGA
3001 CAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCCTGGTATCTTTATAGTCTGTCTGGGTTTCGCCAC
3101 CTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGTCT

PacI (3225)

BspLU11I (3213)

AseI (3251)

3201 GGCCTTTTGCTCACATGTTCTTAATTAATTTTTCAAAGTAGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACTCACTATAGG

MseI (3313)

SfiI (3302)

XcmI (3405)

3301 AGGGCCATCATGGCCAAGTTGACCAGTGTGCCAGTGTCCAGTGTCCAGCCAGGGATGTGGCTGGAGCTGTTGAGTCTGGACTGACAGGTTGGGGTTCCTCA
1▶ M A K L T S A V P V L T A R D V A G A V E F W T D R L G F S
3401 GAGATTTTGTGGAGGATGACTTTGCAGGTGTGGTCAGAGATGATGTACCCTGTTTCATCTCAGCAGTCCAGGACCAGGTGGTGCCTGACAACACCCTGGC
31▶ R D F V E D D F A G V V R D D V T L F I S A V Q D Q V V P D N T L A
3501 TTGGGTGTGGGTGAGAGGACTGGATGAGCTGTATGCTGAGTGGAGTGGGTGCTCCACCACTTCAGGGATGCCAGTGGCCCTGCCATGACAGAGATT
64▶ W V W V R G L D E L Y A E W S E V V S T N F R D A S G P A M T E I
3601 GGAGAGCAGCCCTGGGGGAGAGTTTTGCCCTGAGAGACCCAGCAGGCAACTGTGTGCACTTTGTGGCAGAGGAGCAGGACTGAGGATAAGAATTGTAAC
98▶ G E Q P W G R E F A L R D P A G N C V H F V A E E Q D •

PacI (3734)

3701 AAAAAACCCCGCCCCGGCGGGTTTTTTGTAAATTAA